The Apolipoprotein L1 pipeline drugs market research report outlays comprehensive information on the Apolipoprotein L1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Apolipoprotein L1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Genito Urinary System which include the indications Chronic Kidney Disease (Chronic Renal Failure), and Focal Segmental Glomerulosclerosis (FSGS). It also reviews key players involved in Apolipoprotein L1 targeted therapeutics development with respective active and dormant or discontinued products.
The Apolipoprotein L1 pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 1, 2, 3, and 1 respectively.
Apolipoprotein L1 overview
Apolipoprotein L1 is a protein that in humans is encoded by a gene APOL1. This protein is relatively abundant plasma protein available and involved in the formation of most cholesteryl esters in plasma. It promotes efflux of cholesterol from cells, helps in lipid exchange and transport throughout the body. Apolipoprotein L1 also play a role in reverse cholesterol transport from peripheral cells to the liver and in the inflammatory response. Pro-inflammatory cytokines interferon-γ(IFN), tumor necrosis factor-α (TNF-α) and p53 can increase the expression of APOL.
For a complete picture of Apolipoprotein L1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
